Intas CEO expects to break into U.S. biosimilar market yet this year

The CEO of Intas Pharmaceuticals expects his company to get FDA approval this year for its biosimilar of Amgen's ($AMGN) Neulasta, a drug it developed with Canada's Apotex. That would make it the first of the Indian drugmakers that have been selling biosimilars in their native country to break into the U.S. market, Reuters points out. The U.S. biosimilar market is brand-new, with only Novartis' ($NVS) Zarxio, a copy of Amgen's Neupogen, approved and in the market. Story | More

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.